Drug Giant Fined for Marketing Risperdal as a Dementia Treatment
Posted Nov 13 2013 12:00am
Again, the big pharmaceuticals demonstrate their desire for big profits over good
My late father was given drugs that I found were clearly stated (on-line) to be contraindicated for patients with dementia. I would blame his LTC physician's ignorance, which I later reported, but also the lobbying by drug companies to market their drugs.
The system isn't broken, just abused - horribly, by either ignorant physicians, or those who are ignoring current practices.
In one of the largest health care fraud settlements in U.S. history, pharmaceutical titan Johnson & Johnson (J&J) will shell out $1.7 billion to resolve legal claims surrounding one of its most popular antipsychotics, Risperdal.
The company faces criminal and civil allegations that it—via subsidiary, Janssen Pharmaceuticals—inappropriately marketed Risperdal as a way to manage anxiety and other psychological symptoms in people with dementia.